Published: 10 January 2017
Author(s): Andrea Rubboli, Stefan Agewall, Kurt Huber, Gregory Y.H. Lip
Issue: January 2017
Section: Letter to the Editor

Whereas ongoing oral anticoagulation (OAC), with either warfarin or a non-vitamin K-antagonist oral anticoagulant (NOAC), should generally be confirmed in patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention with stent (PCI-S) [1–2], the type (i.e., warfarin versus NOAC) and dose (i.e., standard versus reduced) of the oral anticoagulant to be added to dual anti platelet therapy of aspirin and clopidogrel (DAPT) when AF develops early after PCI-S need necessarily to be chosen.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.